MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2023-24)
- Udyam number
- UDYAM-HP-10-0000369
Gnosis Pharmaceuticals Private Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2024
₹88.76 Cr
▲ 18% YoY
Net profit · FY 2024
₹1.08 Cr
Net margin 1.2%
EBITDA · FY 2024
₹4.29 Cr
EBITDA margin 4.8%
Authorised capital
₹1.75 Cr
Registered with MCA
Paid-up capital
₹1.57 Cr
Issued & subscribed
Open charges
₹30.33 Cr
Satisfied ₹15.48 Cr
Company age
21 yrs
Est. 2005
Employees · EPFO
309
Provident fund records
About Gnosis Pharmaceuticals Private Limited
Data last updated:
Gnosis Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 17 March 2005 and has been in existence for over 21 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24231DL2005PTC134162. Its GSTIN is 07AACCK5406H2ZP (Delhi). The company holds 6 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹1.75 Cr and a paid-up capital of ₹1.57 Cr. It was formerly known as Kaizen Healthcare Private Limited. It is led by directors including Ramesh Khurana and Rajesh Kumar Khurana.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at House No. B – 102 First Floor Pushpanjali Enclave Pitampura, New Delhi, Delhi, India – 110034.
As per the financials filed for FY 2024, the company reported a revenue of ₹88.76 Cr, a growth of 18% compared to the previous year. For the same year it recorded a net profit of ₹1.08 Cr (net margin 1.2%) and EBITDA of ₹4.29 Cr (EBITDA margin 4.8%). Revenue has grown at a compounded annual rate (CAGR) of 23% over three years and 12% over five years.
The company has about 309 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Gnosis Pharmaceuticals and Gnosis Pharmaceutical. As per MCA filings, the company has open charges of ₹30.33 Cr and satisfied charges of ₹15.48 Cr on record. Court records list 83 cases involving the company, including 19 filed by the company and 64 filed against it; 14 cases are pending. The company has 11 deals on record (9 secondary share transfers, 2 funding rounds), with disclosed funding of ₹1.65 Cr; the latest was in April 2021. Its 8 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 4 smaller; the largest is Sam Fine O Chem Limited with revenue of ₹89.46 Cr.
Gnosis Pharmaceuticals Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-HP-10-0000369). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website gnosispharma.com.
Company details
CIN U24231DL2005PTC134162
Registration Number 134162
Incorporation Date 17 March 2005
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-HP-10-0000369
Recognitions & Rankings of Gnosis Pharmaceuticals
Contact details
Gnosis Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its website is gnosispharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressHouse No. B – 102 First Floor Pushpanjali Enclave Pitampura, New Delhi, Delhi, India – 110034
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Gnosis Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Gnosis Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Gnosis Pharmaceuticals operates two associated brands: Gnosis Pharmaceuticals and Gnosis Pharmaceutical. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures pharmaceutical tablets, syrups, derma products, and offers pharma franchises. | gnosispharmaceuticals.com | |
| Manufactures pharmaceutical drugs including capsules, syrups, and ointments for health needs. | gnosispharma.com |
Business activity
The main business activity of Gnosis Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Gnosis Pharmaceuticals Private Limited, buy the company report.
Financials of Gnosis Pharmaceuticals Private Limited
FY 2024 filings availableGnosis Pharmaceuticals Private Limited reported revenue of ₹88.76 Cr (up 18% YoY) for FY 2024.
Revenue · FY 2024
₹88.76 Cr ▲ 18%
Net profit · FY 2024
₹1.08 Cr margin 1.2%
EBITDA · FY 2024
₹4.29 Cr margin 4.8%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 18%
3 years · compounded
▲ 23%
5 years · compounded
▲ 12%
EBITDA CAGR growth
1 year
▲ 44%
3 years · compounded
▲ 26%
5 years · compounded
▲ 15%
Revenue has grown at a compounded annual rate (CAGR) of 12% over five years, including 18% growth in the latest year. EBITDA rose 44% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹88.76 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹4.29 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.08 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 4.8% | ||||
| Net Profit Margin | 1.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Gnosis Pharmaceuticals Private Limited, buy the company report.
Board of directors of Gnosis Pharmaceuticals Private Limited
Gnosis Pharmaceuticals has 3 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ramesh Khurana Also directs: Wellchem Healthcare LLP, Tycoon Pharmaceuticals Private Limited | Director | 26 Nov 2011 | 14 Years 11 Months | Current |
| Rajesh Kumar Khurana | Director | 26 Nov 2011 | 14 Years 11 Months | Current |
| Surendra Kumar Yadav | Director | 26 Jun 2024 | 2 Years 4 Months | Current |
Peer comparison
Gnosis Pharmaceuticals Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sam Fine O Chem Limited | ₹89.46 Cr (FY 2025) | 22.0% | Rajkot, Gujarat, India | |||
| Medilux Laboratories Pvt Ltd | ₹89.42 Cr (FY 2018) | -2.0% | Indore, Madhya Pradesh, India | |||
| Evertogen Life Sciences Limited | ₹89.28 Cr (FY 2024) | 51.0% | Hyderabad, Telangana, India | |||
| U S Pharma (India) Private Limited | ₹89.26 Cr (FY 2025) | 421.0% | Mumbai, Maharashtra, India | |||
| Gnosis Pharmaceuticals Private Limitedthis company | ₹88.76 Cr (FY 2024) | ₹1.08 Cr | 1.2% | 18.0% | 309 | New Delhi, Delhi, India |
| Martin & Brown Bio-Sciences Private Limited | ₹88.52 Cr (FY 2025) | 75.0% | Nalagarh, Himachal Pradesh, India | |||
| Ravian Life Science Private Limited | ₹88.41 Cr (FY 2025) | 2.0% | Haridwar, Uttarakhand, India | |||
| SRS Pharmaceuticals Private Limited | ₹88.26 Cr (FY 2025) | -10.0% | Mumbai, Maharashtra, India | |||
| Appasamy Ocular Devices Private Limited | ₹87.93 Cr (FY 2022) | 60.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Gnosis Pharmaceuticals Private Limited, buy the company report.
Auditor
Gnosis Pharmaceuticals Private Limited is audited by ARORA VIKAS AND CO. for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| ARORA VIKAS AND CO. | FY 2024 | 030855N |
Shareholding
The shareholding of Gnosis Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Gnosis Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹30.33 Cr
Satisfied charges
₹15.48 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 07 Mar 2024 | 100880638 | Hdfc Bank Limited | ₹20 Lakh | Open | |
| 10 Dec 2021 | 100531011 | Hdfc Bank Limited | ₹25 Lakh | Open | |
| 10 Dec 2021 | 100531013 | Hdfc Bank Limited | ₹24.99 Lakh | Open | |
| 21 Nov 2020 | 100418138 | Hdfc Bank Limited | ₹28.25 Cr | Open | |
| 13 Jul 2018 | 100196840 | Tata Capital Housing Finance Limited | ₹1.08 Cr | Open |
To see the full charge records of Gnosis Pharmaceuticals Private Limited, buy the company report.
Total charge records: 13 View all charges
Deals & funding
Gnosis Pharmaceuticals Private Limited has 11 deals on record (9 secondary share transfers, 2 funding rounds), with disclosed funding of ₹1.65 Cr; the latest was in April 2021.
Total deals
11
Secondary share transfers
9
Funding rounds
2
Disclosed funding
₹1.65 Cr
Deals on record (5 of 11)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2021 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Dec 2012 | Funding round | ₹25 Lakh | Investors: Rajeev Khurana Huf |
| Oct 2012 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 2 individuals |
| Dec 2011 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Oct 2009 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 2 individuals |
To see the full deal history of Gnosis Pharmaceuticals Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Gnosis Pharmaceuticals Private Limited has 83 court cases on record: 19 filed by Gnosis Pharmaceuticals, 64 filed against it. 14 cases are pending and 69 are disposed.
Total cases
83
Filed by the company
19
Filed against the company
64
Pending
14
Disposed
69
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 67 | 49 | 9 |
| High courts | 16 | 15 | 5 |
Cases on record (5 of 83)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, MAHARASHTRA | Court case (CRR) | Filed against the company by Sun Pharma Laboratories Ltd | Pending |
| High Court, MAHARASHTRA | Interim or miscellaneous application | Filed against the company by Sun Pharma Laboratories Ltd W S Kane and Company | Pending |
| High Court | Court case (COMIP) | Filed against the company by Laboratoires Griffon Private Limited and 1 other | Disposed |
| High Court | Interim or miscellaneous application | Filed against the company by Laboratoires Griffon Private Limited and 1 other | Disposed |
| District court, Sirmaur, Himachal Pradesh | Execution petition | Filed by the company against M/S Ecosure Pharma Pvt. Ltd. | Disposed |
To see the full case history of Gnosis Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Gnosis Pharmaceuticals Private Limited was last rated by Crisil on 23 Dec 2016.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 23 Dec 2016 |
To see the full credit ratings and regulatory alerts of Gnosis Pharmaceuticals Private Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Gnosis Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Gnosis Pharmaceuticals Private Limited has a workforce of 309 employees on its EPFO records as of Mar 08, 2025, across 1 active EPFO establishment.
Employee count
309
Active EPFO establishments
1
Employee growth
18.39%
GST
Gnosis Pharmaceuticals has 6 GST registrations: 2 active and 4 cancelled or inactive.
Total GSTINs
6
Active
2
Cancelled / inactive
4
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AACCK5406H2ZP | Delhi | Active | 01 Apr 2021 |
| 02AACCK5406H1Z0 | Himachal Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Gnosis Pharmaceuticals Private Limited, buy the company report.
Recent activity
Gnosis Pharmaceuticals Private Limited has 10 board changes on record since 2008: 3 appointments and 7 cessations. The latest: Surendra Kumar Yadav ceased to be Additional Director on 29 Sep 2024.
AGM
Gnosis Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Ceased
Surendra Kumar Yadav ceased to be Additional Director.
Charges
A charge with Hdfc Bank Limited of Rs. 28.25 Cr registered on 21 Nov 2020 with Charge ID 100418138 was modified on 19 Aug 2024.
Appointed
Surendra Kumar Yadav was appointed as Director.
Filing
Gnosis Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.20 Cr with Charge ID 100880638 was registered on 07 Mar 2024.
Charges
A charge registered on 29 May 2019 via Charge ID 100270199 with Others was fully satisfied on 01 Mar 2023.
Charges
A charge registered on 22 May 2018 via Charge ID 100190185 with Tata Capital Housing Finance Limited was fully satisfied on 25 Jan 2023.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.25 Cr with Charge ID 100531011 was registered on 10 Dec 2021.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.25 Cr with Charge ID 100531013 was registered on 10 Dec 2021.
Ceased
Mool Chandra Sonkar ceased to be Additional Director.
Charges
A charge registered on 18 Jun 2020 via Charge ID 100350086 with Others was fully satisfied on 16 Feb 2021.
23 earlier events are in the company report.
Frequently asked questions
Gnosis Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 17 March 2005 (21+ years old) and is registered under CIN U24231DL2005PTC134162.
Gnosis Pharmaceuticals has 3 current directors:
- Ramesh Khurana - Director
- Rajesh Kumar Khurana - Director
- Surendra Kumar Yadav - Director
The latest financial statements of Gnosis Pharmaceuticals on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Gnosis Pharmaceuticals is 07AACCK5406H2ZP, registered in Delhi. The company has 6 GST registrations in all, of which 2 are active and 4 are cancelled or inactive. Other active GSTINs include 02AACCK5406H1Z0 (Himachal Pradesh).
The CIN (Corporate Identification Number) of Gnosis Pharmaceuticals is U24231DL2005PTC134162. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Gnosis Pharmaceuticals has 83 court cases on record: 19 filed by the company and 64 filed against it. 14 are pending. Most are in the district courts.
Gnosis Pharmaceuticals was incorporated on 17 March 2005, making it 21+ years old. It is registered with the Registrar of Companies, Delhi.
Gnosis Pharmaceuticals has 11 deals on record (9 secondary share transfers, 2 funding rounds), with disclosed funding of ₹1.65 Cr; the latest was in April 2021.
The peers of Gnosis Pharmaceuticals by revenue are Sam Fine O Chem Limited, Medilux Laboratories Pvt Ltd, Evertogen Life Sciences Limited, U S Pharma (India) Private Limited, Martin & Brown Bio-Sciences Private Limited and 3 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Surendra Kumar Yadav ceased to be Additional Director on 29 Sep 2024. Surendra Kumar Yadav was appointed as Director on 26 Jun 2024. Mool Chandra Sonkar ceased to be Additional Director on 25 Nov 2021. Gnosis Pharmaceuticals has 10 board changes on record in total.
Yes, Gnosis Pharmaceuticals is registered as a medium enterprise under Udyam registration (number: UDYAM-HP-10-0000369).